- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
How Has COVID-19 Impacted the Allergy and Immunology Field?
Courtney Blair, MD, discusses how COVID-19 has impacted patients with allergies and other respiratory conditions.
With unprecedented pauses in air pollution emissions seen around the world in the spring of 2020 and virus mitigation behaviors being implemented for over a year, the COVID-19 pandemic has presented a unique opportunity to better understand the impact of poor air quality on human health.
In particular, exposure reduction due to mask-wearing and stay-at-home orders has contributed to anecdotal reports of reduced exacerbations among patients with chronic obstructive pulmonary disease (COPD), asthma, allergies, and other respiratory conditions.
To learn more about how the pandemic has altered care and disease management among these patients, we spoke with Courtney Blair, MD, an allergist and immunologist in Virginia.
On this episode of Managed Care Cast, Blair, who also serves as the president of the Greater Washington Allergy, Asthma, and Immunology Society, discusses factors that may have contributed to improvements in her patients’ respiratory health over the past 15 months.
Listen above or through one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
